Heidelberg Pharma Announces AGM Results and New Supervisory Board

Heidelberg Pharma AG, a biotech company focused on Antibody Drug Conjugates (ADCs), held its 2025 Annual General Meeting virtually. Key management proposals received overwhelming approval, with vote percentages ranging from 98.03% to 99.99%. Key agenda items included the appointment of auditors for the 2024/2025 financial year and approval of compensation for the Management and Supervisory Boards.

Significant changes to the Supervisory Board were announced, with Dr Karl Benedikt Biesinger and Dr Klaus Schollmeier joining. Dr Biesinger was elected as Chairman. Departing members, including Professor Christof Hettich, were acknowledged for their service. CEO Andreas Pahl expressed gratitude to outgoing members and welcomed the new appointees.

Dr Biesinger emphasized the company's potential in the growing ADC market. Shareholder attendance via postal votes was 81.45%. Further details on voting results are available on the company's website.